vimarsana.com

Latest Breaking News On - Products development grant - Page 1 : vimarsana.com

HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

Christopherj schaberHellen kimUs congressUs developmentDermatology departmentDrug administrationUniversity of pennsylvaniaSoligenix incPenn cutaneous lymphoma programBiomedical advanced researchDefense threat reduction agencyOur public health solutionsProducts development grantHospital of the university pennsylvaniaExchange commissionProducts development

Soligenix s HyBryte receives $2 6M in support from FDA

The FDA awarded Soligenix a grant for the development of HyBryte for treatment in patients with early-stage cutaneous T-cell lymphoma.

Christopher schaberSoligenix incEuropean medicines agencyDrug administrationProducts development grantOrphan products development grant

vimarsana © 2020. All Rights Reserved.